United States: Guest Post – Failure To Warn Claim Dead On Arrival Without Testimony From Prescribing Physician

Last Updated: January 9 2017
Article by James Beck

This is a guest post from Michael Salimbene, an associate at Reed Smith. It's about learned intermediary causation, and the need for prescriber testimony. Not infrequently, in mass torts with lots of solicited plaintiffs, the other side puts off doing anything, including preserving prescriber testimony, for as long as possible. If the prescriber dies or disappears, plaintiffs don't have any causation testimony, and since they bear the burden of proof, that's a problem for them. The guest post describes the latest example. As always our guest poster deserves 100% of the credit (it's not our work), and any blame, for what follows.

*********

This guest blogger lives just outside of Philadelphia. In this neck of the woods, the post-holiday, pre-Spring window is perhaps the most universally loathed time of year. It's filled with grey skies and frigid winds. Partner in-office attendance, which tends to wane during the summer months and late December, hits its yearly high. The all-important billable hour "clock" resets to 0. Street corner sales of unlicensed Carson Wentz tee shirts have stalled, and playoff football will feature two of Philadelphia's most hated rivals, the Giants and the Cowboys. Your children, if anything like this guest blogger's, will ignore the Frozen-themed electric car that "Santa" left (but took you 4 hours to assemble) in favor of a $6 pair of pink bunny slippers. So for today's post, in search of some good news, we travel to the Middle District of Georgia where the temperature hovers just above 60 degrees. In a few short months, Northeasterners will also be enjoying warm skies and Georgia's finest offering, The Masters. Until then, we'll have to make due with favorable warning-causation decisions like this one.

Today's case comes to us from the Mentor Corp. Obtape Transobturator Sling Products Liability Litigation MDL in the Middle District of Georgia. In re Mentor Corp. ObTape Transobdurator Sling Prods. Liab. Litig., No. 4:13-cv-229, 2016 WL 4611572 (M.D. Ga. Sept. 2, 2016). We've blogged about this MDL quite a bit ( recently here, here, and here). As were most plaintiffs in the ObTape litigation, this plaintiff's prescribing surgeon treated her for a form of incontinence with the relevant device. If you've watched daytime TV in the past 5 years, you'll be familiar with the typical list of complaints that undergird vaginal mesh lawsuits: mesh "erosion" or "extrusion" (movement of the mesh material into surrounding tissue); "dyspareunia" (painful intercourse); and the need to have additional surgery to correct mesh-related complications, to name a few. Plaintiff never had her mesh removed, but alleged, among other things, that the product caused her to suffer from chronic pain. So what makes this case different from the thousands of other mesh cases pending across the nation? Plaintiff's implanting physician died before he could testify in her case.

Defendant moved for partial summary judgment, and, because Plaintiff abandoned all her other theories attacked by the motion, the only issue the Court needed to resolve was Plaintiff's claim for strict liability failure to warn. Nobody disputed that the law of Plaintiff's home state, Texas, applied.

Like just about everywhere else, Texas follows the learned intermediary doctrine, which "requires a prescription medical device manufacturer to provide an adequate warning about the device's risks to the prescribing physician and not to the patient directly. Id. at *2 (citing Centocor, Inc. v. Hamilton, 372 S.W.3d 140, 157 (Tex. 2012)). Under Texas law, a plaintiff must prove both that defendant failed to provide an adequate warning regarding the product at issue and that the inadequate warning caused the plaintiff's injury. Stated differently, to prevail on her failure to warn claim, Plaintiff had to establish that her prescribing physician "would have acted differently had [Defendant] provided a different warning" about the product. Id.

And that's where things got tricky for Plaintiff. Because her implanting surgeon was deceased, securing direct testimony regarding the effect of an alternative warning was out the window. By "direct testimony," we mean the questions that seem to make up the bulk of plaintiff lawyer's deposition outlines, which go something like this: "Wouldn't you like to have known if [evil defendant company] knew [insert bad thing that could purportedly happen based on unseemly internal company emails that won't be shown to the witness because they may not even exist]?" As a result, Plaintiff was forced to trot out a two-pronged strategy that involved (1) the heeding presumption ( which we've covered a fair amount) and (2) her expert "filling-in-the-blanks." Neither worked.

First, the Court made short work of the heeding presumption, noting that the Fifth Circuit Court of Appeals "has expressed doubt that Texas courts would hold that this presumption applies in cases involving prescription drugs or devices." Id. (citing Ackermann v. Wyeth Pharm., 526 F.3d 203, 212 (5th Cir. 2008)) ("[N]either Texas nor federal courts applying Texas law have applied the read-and-heed presumption to pharmaceutical cases involving learned intermediaries"). Even if Texas did follow the heeding presumption in medical device cases, "it would simply permit the Court to presume that [Plaintiff's implanting surgeon] would have considered [the product's] [purported] risks . . . in determining which product to select for [Plaintiff]. The presumption does not, however, permit the Court to speculate about how [Plaintiff's implanting surgeon] would have weighed the additional warnings." Id. at *3.

Second, with the Court unwilling to speculate, welcome to the fold an expert witness, who was perfectly content to "opine" (cough...speculate) that: "(1) [Plaintiff's implanting surgeon] likely did not know that [the product] had certain risks that were not disclosed in the product insert data sheet, and (2) a reasonable physician in [Plaintiff's implanting surgeon's] position would have told his patients about all of these additional risks had he known of them." Id. But these opinions missed the mark. Under Texas law, it does not matter what a "reasonable" physician would do. Causation is not determined in the abstract. Rather, Plaintiff must demonstrate that a different warning would have caused the plaintiff's own doctors to stop prescribing the product at issue. Id. (citing Centocor, 372 S.W.3d at 172-73). Plaintiff had no such evidence. Moreover, Plaintiff lacked evidence that, if presented with an "adequate" warning, she herself would have done something different (i.e., withheld consent to surgery). Id. Exactly what that might be, the Court did not explain.

Plaintiff's expert therefore crawled further out on the causal limb to offer the opinion that Plaintiff's implanting surgeon "[m]ore likely than not ... would have altered his clinical practice in treating [Plaintiff's medical condition]" if he had received additional warnings about Defendant's product "in that he would have not offered [the product] as option to [Plaintiff], would have offered additional options to [Plaintiff] and/or would have relayed additional safety information from [the company to Plaintiff]." Id. This opinion would be more credible coming from Miss Cleo than an OBGYN. The Court seemed to agree.

[An expert] cannot offer an expert opinion unless it is based on "sufficient facts or data," Fed. R. Evid. 702(b), and [Plaintiff] did not point to anything in the present record to suggest that [her expert's] opinion on this point is supported by any facts or data about [Plaintiff's implanting surgeon's] practices, including how [he] evaluated the risks and benefits of the products he implanted in his patients.

Id. And with that, the Court granted Defendant summary judgment on Plaintiff's strict liability failure to warn claim.

We think this is a fair result. Plaintiff bore the burden of proof, and her complaint was filed eight years after the implant surgery in question. A tardy plaintiff bears the risk that sources of evidence will disappear in the interim. This is a recurring issue. One of this year's top 10 decisions, "Accutane I," dealt with this issue, and held under the laws of 35 jurisdictions that warning causation under the learned intermediary rule necessarily fails where the death or disappearance of the actual prescriber precludes the affirmative testimony necessary to satisfy a plaintiff's burden of proof. Accutane I was discussed here. A couple years ago, the blog published a " little list" of decisions that, like the one here, refuse to allow plaintiffs to shirk their causation burden where, for whatever reason, a prescribing doctor's testimony was not obtained. Texas was the first state discussed in that list, and this case adds to a growing body of favorable law. Moreover, the ObTape MDL has been a solid contributor to this body law. Today's post comes on the heels of an ObTape decision we blogged about that reached the same conclusion under Florida law.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.